NanoRepro AG (FRA:NN6)

Market Cap	23.71M -1.8%
Revenue (ttm)	4.34M -3.0%
Net Income	-1.99M
EPS	-0.16
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.780
Previous Close	1.785
Day's Range	1.780 - 1.780
52-Week Range	1.310 - 2.260
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 30, 2026

About NanoRepro AG

NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. It offers rapid diagnostic tests, such as family planning, and preventive healthcare line products. The company also develops and commercializes immunochromatographic lateral flow tests; and tests for hospitals and medi...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2006
• Employees: 22
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NN6

Financial Performance

In 2025, NanoRepro AG's revenue was 4.34 million, a decrease of -3.02% compared to the previous year's 4.47 million. Losses were -1.99 million, -2.87% less than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error